Nitrosourea derivatives for the treatment of Hodgkin's disease involving the central nervous system: a study of 23 cases.
This study deals with the effectiveness of nitrosourea derivatives (nitrosomethylurea and CCNU) used as single agents or in combination with vinca alkaloids, procarbazine and prednisolone in 23 patients suffering from Hodgkin's disease with spinal cord or intracranial involvement. Complete regression of neurologic symptoms was observed in 61% of patients with spinal cord compression and in 4 out of 5 cases of brain involvement. No relationship was found between type, degree and duration of symptoms, and treatment efficacy.
Gershanovich
M L
ML
Department of Clinical Chemotherapy, NN Petrov Research Institute of Oncology, USSR Ministry of Health, Leningrad.
Arkhipov
A I
AI
Vilensky
B S
BS
D000293:Adolescent; D000328:Adult; D001927:Brain Diseases / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006689:Hodgkin Disease / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use*; D008297:Male; D008770:Methylnitrosourea / Q000627:therapeutic use*; D008875:Middle Aged; D009367:Neoplasm Staging; D013117:Spinal Cord Compression / Q000188:drug therapy / Q000209:etiology; D016019:Survival Analysis
D008770:Methylnitrosourea; D008130:Lomustine